PolyPid’s D-PLEX₁₀₀ Shows Promise in Reducing Surgical Site Infections, Secures $26.7 Million Funding
PolyPid Ltd., a biopharmaceutical company, has recently announced a significant advancement in its quest to combat surgical site infections (SSIs) with its D-PLEX₁₀₀ technology. The company has secured $26.7 million through warrant exercises, a move that extends its financial runway beyond the anticipated FDA approval of D-PLEX₁₀₀. This development comes on the heels of successful […]